Electronic Journal of General Medicine

• Moehler TM, Ho AD, Goldschmidt H, Barlogie B. Angiogenesis in hematologic malignancies. Crit Rev Oncol Hematol 2003;45:227-44.
• Longo V, Vacca A, Ribatti D. Imaging and angiogenesis in hematological malignancies. Leukemia 2007; 21: 1605.
• De Vita VT, Hellman S, Rosenberg SA. Molecular biology of cancer: Invasion and metastasis. In: Fıdler IJ, eds. Cancer: Principles and Practice of Oncology 5 th. ed. LippincottLaven Pub. Philadelphia,. 1997; pp. 7: 135-41.
• Ferrara N. VEGF: An update on biological and therapeutic aspects. Curr Opin Biotechnol 2000;11:517-24.
• Klagsbrun M, D’Amore P. Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev 1996;7:259-70.
• Fayette J, Soria JC, Armand JP. Use of angiogenesis inhibitors in tumour treatment. Eur J Cancer 2005;41:1109-16.
• Ferrara N, Gerber HP, Le Couter. The biology of VEGF and its receptors. Nat Med 2003;9:669–76.
• Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. The vascular endothelial growth factor family: Identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 1991;5:1806–14.
• Tischer E, Mitchell R, Hartman T. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991;266:11947–54.
• Kumar S, Witzig TE, Timm M, et al. Expression of VEGF and its receptors by myeloma cells. Leukemia 2003;17: 2025–31.
• Aguayo A, Kantarjian H, Manshouri T, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000;96:2240-45.
• Fiedler W, Graeven U, Ergün S, et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 1997;89:1870-75.
• Aguayo A, Estey E, Kantarjian H. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 1999;94:3717-21.
• Lundberg LG, Lerner R, Sundelin P, Rogers R, Folkman J, Palmblad J. Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity. Am J Pathol 2000;157:15-9.
• Parikh AA, Ellis LM. The vascular endothelial growth factor family and its receptors. Hematol Oncol Clin North Am 2004;18:951–71.
• Wang JY. Abl tyrosine kinase in signal transduction and cell-cacle regulation. Curr Opin Genet Dev 1993;3:35-43.
• Deisseroth AB, Andreeff M, Champlin R. Chronic Leukemias. In: V.T. DeVita eds. Cancer: principles and practice of oncology. JB Lippincott Company, Philadelphia. 1994; pp: 1965-79.
• Quintas-Cardama A, Kantarjian H, Cortes J. Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov 2007;6:834–48
• Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007;6:273–86.
• Faivre S, Demetri G, Sargent W. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007;6:734–45.
• Motzer RJ, Bukowski RM. Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 2006;24:5601–8.
• Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125–34.
• Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR-ABL–positive cells. Nat Med 1996;2:561-6.
• Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European Leukemia Net. Blood 2006;108:1809-20.
• Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000;96:925-32.
• Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305:399-401.
• Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354:2531-41.
• Ratajczak MZ, Ratajczak J, Machalinski B, et al. Role of vascular endothelial growth factor (VEGF) and placentaderived growth factor (PlGF) in regulating human haemopoietic cell growth. Br J Haematol 1998;103:969-79.
• Aguayo A, O'Brien S, Keating M, et al. Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia. Blood 2000;96:768-70.
• Verstovsek S, Kantarjian H, Manshouri T, et al. Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia. Blood 2002;99:6:2265-7.
• Legros L, Bourcier C, Jacquel A, et al. Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia. Blood 2004;104:495-501.
• Kvasnicka HM, Thiele J, Staib P, et al. Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy. Blood 2004;103:3549–51
• Liu Y, Wang Z, Kwong SQ, et al. Inhibition of PDGF, TGF-β, and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib. J Hepatol 2011;55:612-25.
• Deprimo SE, Friece C, Huang X, et al. Effect of treatment with sunitinib malate, a multitargeted tyrosine kinase inhibitor, on circulating plasma levels of VEGF, soluble VEGF receptors 2 and 3, and soluble KIT in patients with metastatic breast cancer. J Clin Oncol 2006;24:18:578.
• Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2012;119:5:1123-9.
• Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus Imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-9.

Vancouver

Yıldırım R, Sincan G, Pala Ç, Düdükcü M, Kaynar L, Urlu SM, et al. Effects of Imatinib, Nilotinib, Dasatinib on VEGF and VEGFR-1 Levels in Patients with Chronic Myelogenous Leukemia. EUR J GEN MED. 2016;13(2):111-5. https://doi.org/10.15197/ejgm.1527

APA

Yıldırım, R., Sincan, G., Pala, Ç., Düdükcü, M., Kaynar, L., Urlu, S. M., Kiki, İ., Erdem, F., Çetin, M., Gündoğdu, M., & Topdağı, Ö. (2016). Effects of Imatinib, Nilotinib, Dasatinib on VEGF and VEGFR-1 Levels in Patients with Chronic Myelogenous Leukemia. European Journal of General Medicine, 13(2), 111-115. https://doi.org/10.15197/ejgm.1527

AMA

Yıldırım R, Sincan G, Pala Ç, et al. Effects of Imatinib, Nilotinib, Dasatinib on VEGF and VEGFR-1 Levels in Patients with Chronic Myelogenous Leukemia. EUR J GEN MED. 2016;13(2), 111-115. https://doi.org/10.15197/ejgm.1527

Chicago

Yıldırım, Rahşan, Gülden Sincan, Çiğdem Pala, Musa Düdükcü, Leylagül Kaynar, Selin Merih Urlu, İlhami Kiki, Fuat Erdem, Mustafa Çetin, Mehmet Gündoğdu, and Ömer Topdağı. "Effects of Imatinib, Nilotinib, Dasatinib on VEGF and VEGFR-1 Levels in Patients with Chronic Myelogenous Leukemia". European Journal of General Medicine 2016 13 no. 2 (2016): 111-115. https://doi.org/10.15197/ejgm.1527

Harvard

Yıldırım, R., Sincan, G., Pala, Ç., Düdükcü, M., Kaynar, L., Urlu, S. M., . . . Topdağı, Ö. (2016). Effects of Imatinib, Nilotinib, Dasatinib on VEGF and VEGFR-1 Levels in Patients with Chronic Myelogenous Leukemia. European Journal of General Medicine, 13(2), pp. 111-115. https://doi.org/10.15197/ejgm.1527

MLA

Yıldırım, Rahşan et al. "Effects of Imatinib, Nilotinib, Dasatinib on VEGF and VEGFR-1 Levels in Patients with Chronic Myelogenous Leukemia". European Journal of General Medicine, vol. 13, no. 2, 2016, pp. 111-115. https://doi.org/10.15197/ejgm.1527